TYPE-I DIABETES MASQUERADING AS TYPE-II DIABETES - POSSIBLE IMPLICATIONS FOR PREVENTION AND TREATMENT

被引:48
作者
LESLIE, RDG
POZZILLI, P
机构
[1] ST BARTHOLOMEWS HOSP, DEPT DIABET & METAB, LONDON, ENGLAND
[2] UNIV ROMA LA SAPIENZA, CATTEDRA ENDOCRINOL 1, ROME, ITALY
关键词
D O I
10.2337/diacare.17.10.1214
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type I diabetes is probably due to the immune-mediated destruction of islet insulin-secreting beta-cells. This chronic destructive process is associated with both cellular and humoral immune changes in the peripheral blood that can be detected months, even years, before the onset of clinical diabetes. Throughout this prediabetic period, metabolic changes, including altered glucose tolerance and reduced insulin secretion, deteriorate at variable rates toward full-blown diabetes. The ability to predict subsequent clinical diabetes in those nondiabetic individuals with immune and metabolic changes has led to attempts to prevent the disease onset by therapeutic intervention. A small fraction of individuals with immune changes develop clinical diabetes that does not require insulin treatment. The onset of diabetes in these cases is usually in adult life, and because their diabetes is, at least initially, not insulin-dependent, they appear clinically to have type II diabetes. Such patients probably have the same disease process as patients with type I diabetes in that they have similar human leukocyte antigen (HLA) genetic susceptibility as well as autoantibodies to islet antigens. It is proposed that non-insulin-dependent diabetic patients who have markers that characterize individuals at risk of type I diabetes may be suitable candidates for those same therapeutic strategies that seek to prevent progression to insulin-dependence or even to reestablish normal glucose tolerance.
引用
收藏
页码:1214 / 1219
页数:6
相关论文
共 47 条
  • [1] DEPENDENCE OF ANTIGEN EXPRESSION ON FUNCTIONAL-STATE OF BETA-CELLS
    AAEN, K
    RYGAARD, J
    JOSEFSEN, K
    PETERSEN, H
    BROGREN, CH
    HORN, T
    BUSCHARD, K
    [J]. DIABETES, 1990, 39 (06) : 697 - 701
  • [2] INSULITIS AND DIABETES IN NOD MICE REDUCED BY PROPHYLACTIC INSULIN THERAPY
    ATKINSON, MA
    MACLAREN, NK
    LUCHETTA, R
    [J]. DIABETES, 1990, 39 (08) : 933 - 937
  • [3] RISK FOR DEVELOPING TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS AND THE PRESENCE OF ISLET 64K ANTIBODIES
    BARMEIER, H
    MCCULLOCH, DK
    NEIFING, JL
    WARNOCK, G
    RAJOTTE, RV
    PALMER, JP
    LERNMARK, A
    [J]. DIABETOLOGIA, 1991, 34 (10) : 727 - 733
  • [4] IMPAIRED GLUCOSE-TOLERANCE PRECEDES BUT DOES NOT PREDICT INSULIN-DEPENDENT DIABETES-MELLITUS - A STUDY OF IDENTICAL-TWINS
    BEER, SF
    HEATON, DA
    ALBERTI, KGMM
    PYKE, DA
    LESLIE, RDG
    [J]. DIABETOLOGIA, 1990, 33 (08) : 497 - 502
  • [5] AGE-DEPENDENT HLA GENETIC-HETEROGENEITY OF TYPE-1 INSULIN-DEPENDENT DIABETES-MELLITUS
    CAILLATZUCMAN, S
    GARCHON, HJ
    TIMSIT, J
    ASSAN, R
    BOITARD, C
    DJILALISAIAH, I
    BOUGNERES, P
    BACH, JF
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (06) : 2242 - 2250
  • [6] ANTIBODIES TO GAD AND TRYPTIC FRAGMENTS OF ISLET 64K ANTIGEN AS DISTINCT MARKERS FOR DEVELOPMENT OF IDDM - STUDIES WITH IDENTICAL-TWINS
    CHRISTIE, MR
    TUN, RYM
    LO, SSS
    CASSIDY, D
    BROWN, TJ
    HOLLANDS, J
    SHATTOCK, M
    BOTTAZZO, GF
    LESLIE, RDG
    [J]. DIABETES, 1992, 41 (07) : 782 - 787
  • [7] FOULIS AK, 1984, DIABETOLOGIA, V26, P456
  • [8] INSULIN USE IN NIDDM
    GENUTH, S
    [J]. DIABETES CARE, 1990, 13 (12) : 1240 - 1264
  • [9] BETA-CELL FUNCTION IN RELATION TO ISLET-CELL ANTIBODIES DURING THE 1ST 3 YR AFTER CLINICAL-DIAGNOSIS OF DIABETES IN TYPE-II DIABETIC-PATIENTS
    GOTTSATER, A
    LANDINOLSSON, M
    FERNLUND, P
    LERNMARK, A
    SUNDKVIST, G
    [J]. DIABETES CARE, 1993, 16 (06) : 902 - 910
  • [10] GOTTSATER A, 1992, DIABETES NUTR METAB, V5, P243